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We report that many histone modiﬁcations are unevenly distributed over the HPV16 genome in cervical
cancer cells as well as in HPV16-immortalized keratinocytes. For example, H3K36me3 and H3K9Ac that
are common in highly expressed cellular genes and over exons, were more common in the early than in
the late region of the HPV16 genome. In contrast, H3K9me3, H4K20me3, H2BK5me1 and H4K16Ac were
more frequent in the HPV16 late region. Furthermore, a region encompassing the HPV16 early
polyadenylation signal pAE displayed high levels of histone H3 acetylation. Histone deacetylase (HDAC)
inhibitors caused a 2- to 8-fold induction of HPV16 early and late mRNAs in cervical cancer cells and in
immortalized keratinocytes, while at the same time increasing the levels of acetylated histones in the
cells and on the HPV16 genome speciﬁcally. We concluded that increased histone acetylation on the
HPV16 genome correlates with increased HPV16 gene expression.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Human papillomavirus (HPV) is the most common sexually
transmitted virus in the human population. It is present in 99.7% of
all cervical cancers and is tightly associated with other anogenital
cancers as well as head and neck cancers (Walboomers et al.,
1999). More than 500,000 cases of cervical cancers are diagnosed
each year in the world and cervical cancer is one of the main
causes of death of women in the developing world (Walboomers
et al., 1999). Although the vast majority of the genital HPV
infections are cleared by the immune system within a year after
infection, and as such pose little threat to the health of the infected
individual, HPVs may in rare cases persist and cause cancer (zur
Hausen, 2002). These persistent HPV infections are generally
caused by a subset of the sexually transmitted HPVs termed
high-risk HPV types. HPV type 16 is the most common high-risk
type in cervical cancers as well as in the human population
(Bouvard et al., 2009; Bosch et al., 2002). How HPV16 can persist
in the presence of a functional immune system is an enigma but is
likely a result of the ability of HPV16 to interfere with the immune
system of the host, and its ability to restrict expression of the
highly immunogenic L1 and L2 capsid proteins to a late stage in
the viral life cycle, at the very top of the infected mucosal
epithelium (Chow et al., 2010; Bodily and Laimins 2011; Doorbar,
2005). Controlling HPV16 gene expression is therefore of para-
mount importance for establishment of persistence (Johansson
and Schwartz, 2013).
The HPV16 DNA genome can be divided into an early and a late
region (Fig. 1A) (Howley and Lowy, 2006). The early region is
coding for E1, E2, E4, E5, E6 and E7 and is followed by the early
polyA signal pAE, while the late region encodes L1 and L2 and is
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Fig. 1. (A) Schematic representation of the HPV16 genome depicting open reading frames as rectangles, the early and late promoters p97 and p670 respectively, as arrows and splice
sites as triangles. The long control region (LCR) and the early and late polyA signals pAE and pAL are indicated. Schematic drawing of the HPV16 pBELsLuc reporter plasmid integrated
in the cellular genome of the C33A-derived reporter cell line C33A2 (Li et al., 2013). A subset of early and late mRNAs that may be produced from the pBELsLuc is indicated. The
locations of amplicons produced in ChIP assays with primers listed in Table S1 are indicated. (B) DNA extracted from MNase treated chromatin prepared from C33A2 cells were
separated on agarose gels and stained with GelRed nucleic acid staining. LM and HM indicated low and high levels of MNase, respectively. The higher levels yielded primarily
monosomes and were used for all preparations. (C) PCR of HPV16 DNAwith primers L2F and L2R (L2 amplicon) on chromatin immunoprecipitations performed with IgG, anti-histone
H3- or anti-RNA polymerase-II-antibodies on two independently prepared nucleosome preparations. PCR with the same primers was also performed on each nucleosome preparation
that was used for ChIP (input). (D–F) ChIP analyses on C33A2 cells using antibodies to proteins indicated in each histogram and qPCR of the indicated amplicons. Primers and
antibodies are listed in Tables S1 and S2 respectively. Mean values with standard deviations of the amount of immunoprecipitated DNA compared to input DNA are displayed. For
antibodies to H3, H4 and RNA polymerase II, the values for the CMVtata PCR was set to 1 to correct for differences between different ChIP extracts. White bars represent HPV16 early
genes and gray bars represent late genes. p-Values were calculated for each ChIP result in relation to the CMVtata amplicon (D) or the E1 amplicon (E, F and H). p-Values less than 0.05
(n) or 0.01 (nn) are indicated. All samples were analyzed in two independent ChIP assays and all qPCR reactions were performed in triplicates. (G) Secreted luciferase activity in the cell
culture medium of C33A2 cells incubated with 5 μM of the indicated demethylase inhibitors for 24 h. DMSO was used as a negative control and TPA as a positive control. Graph shows
mean values and standard deviations of fold induction of sLuc activity of each drug compared to DMSO. Results are from three independent experiments performed in triplicates. p-
Values were calculated with sLuc results from each drug compared to sLuc results from C33A2 cells incubated with DMSO. All sLuc measurements were obtained from at least three
independent cell treatments and were analyzed in triplicates. p-Values less than 0.05 (n) or 0.01 (nn) are indicated. (H) Chromosomal DNA prepared from C33A2 cells subjected to
methyl-cytosine DNA immunoprecipitation followed by qPCR of the indicated amplicons. p-Values were calculated for each primer pair in relation to the E1 amplicon. p-Values less
than 0.05 (n) or 0.01 (nn) are indicated. All samples were analyzed in two independent assays and all qPCR reactions were performed in triplicates. (I) sLuc activity in the cell culture
medium of C33A2 cells incubated with 5 μM of the indicated DNA methyltransferase inhibitors azacitidine or RG108. p-Values were calculated with sLuc results from each drug
compared to sLuc results from C33A2 cells incubated with DMSO. All sLuc measurements were obtained from at least three independent cell treatments and were analyzed in
triplicates. None of the p-values were less than 0.05.
followed by the late polyA signal pAL. The early promoter p97 is
situated upstream of the E6 gene and could potentially produce
mRNAs encoding all HPV proteins, while the late promoter p670 is
situated upstream of the E1 gene and therefore cannot be used
to express the E6 and E7 genes (Schwartz, 2013; Baker and
Calef, 1997). HPV16 gene expression is controlled at the level of
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Fig. 1. (continued)
C. Johansson et al. / Virology 482 (2015) 244–259246
transcription (Bernard, 2013), which is regulated by both HPV16
E2 and by cellular factors (McBride, 2013; Thierry, 2009). HPV16
gene expression is also regulated at the level of polyadenylation
which includes a switch from the early polyA signal (pAE) to the
late polyA signal (pAL), and at the level of splicing as evidenced by
the high number of alternatively spliced mRNAs that produced
during the viral life cycle (Johansson and Schwartz, 2013;
Schwartz, 2013; Graham, 2008; Jia and Zheng, 2009).
The efﬁciency by which a splice site is used is determined by
cis-acting regulatory RNA elements termed splicing enhancers and
silencers (Cartegni et al., 2002). Many of the HPV16 splice sites are
controlled by cis acting RNA elements (Johansson and Schwartz,
2013). For example, the efﬁciently used 30-splice site SA3358 used
by both early and late HPV16 mRNAs is dependent on a strong
splicing enhancer located downstream of SA3358 (Rush et al.,
2005; Somberg and Schwartz, 2010; Li et al., 2013). This enhancer
interacts with ASF/SF2 (SRSF1), SRp30c (SRSF9) and SRp20 (SRSF3)
(Somberg and Schwartz, 2010; Li et al., 2013; Somberg et al., 2011;
Jia et al., 2009, 2010). Lack of splicing to SA3358 reduces poly-
adenylation at pAE, demonstrating that the splicing enhancer
downstream of SA3358 is a key regulatory element in the HPV16
life cycle (Rush et al., 2005; Li et al., 2013). Furthermore, HPV16
late splice sites SD3632 and SA5639 that are used exclusively to
produce the late L1 mRNAs, are under control of splicing silencers
that interact with hnRNP A1 for SA5639 (Zhao et al., 2004, 2007;
Zhao and Schwartz, 2008), and with hnRNP D-proteins and hnRNP
A2/B1 for SD3632 (Li et al., 2013). On the other hand, hnRNP A1
enhances splicing of the HPV16 early mRNAs (Rosenberger et al.,
2010). The HPV16 early polyA signal is also subject to regulation,
and a reduction in polyadenylation efﬁciency is required for
activation of HPV16 late gene expression (Zhao et al., 2005; Jeon
and Lambert, 1995). The HPV16 E2 protein interferes with the
polyadenylation complex at pAE thereby inducing HPV16 late gene
expression (Johansson et al., 2012). The HPV16 early polyA signal is
under positive control of the upstream, untranslated region (Zhao
et al., 2005; Jeon and Lambert, 1995) and by downstream elements
spanning the L2 coding region (Oberg et al., 2005). In contrast, the
late polyA signal is strongly suppressed by sequences in the late
UTR that are active at least in mitotic cells (Graham, 2008). Thus,
RNA processing plays a major role in HPV16 gene regulation
(Johansson and Schwartz, 2013).
Although it is well established that the state of the chromatin
control transcription of cellular genes, recently published results
indicate that chromatin and epigenetic properties of chromosomal
DNA within genes such as nucleosome positioning, histone
methylation, acetylation and phosphorylation may contribute to
the control of RNA splicing and polyadenylation by recruiting
RNA processing factors to DNA sequences encoding splicing
regulatory RNA elements (Braunschweig et al., 2013; Brown
et al., 2012; Acuna et al., 2013; Schwartz and Ast, 2010; Luco
and Misteli, 2011; Iannone and Valcárcel, 2013). For example,
H3K36me3 and H3K9me3 are enriched over exons and may
recruit splicing factors (Barski et al., 2007; Wang et al., 2008;
Luco et al., 2010; Pradeepa et al., 2012; Saint-Andre et al., 2011),
while high levels of H3K9Ac are associated with exon skipping
(Zhou et al., 2011; Schor et al., 2009). Posttranslational modiﬁca-
tions of histones on the HPV16 genome could therefore potentially
control HPV16 gene expression. It has also recently been shown
that the HPV16 genome is subject to epigenetic modiﬁcations over
the viral replication cycle, in particular DNA methylation although
the signiﬁcance of these modiﬁcations is unclear (Szalmás and
Kónya, 2009; Steenbergen et al., 2014). Furthermore, chromatin
immunoprecipitations performed on HeLa cell chromatin have
indicated that histone marks on the HPV18 sequences in HeLa cells
are unevenly distributed over the HPV18 genome, suggesting a
role for histone modiﬁcations in the control of HPV18 gene
expression (Johannsen and Lambert, 2013). The papillomavirus
E2 proteins interact with chromatin and could potentially control
gene expression by interfering with histone function (McBride et
al., 2012). We therefore wished to investigate if epigenetic proper-
ties of the HPV16 genome could potentially control HPV16 gene
expression.
Results
Low levels of H3K36me3 and high levels of H3K9me3, H4K20Me3 and
H2BK5me1 in the HPV16 late genes in cervical cancer cells
In order to investigate if epigenetic properties of the HPV16
genome such as DNA methylation and histone modiﬁcations
contribute to HPV16 gene regulation, we used the HPV16 reporter
cell line C33A2 (Fig. 1A). This cell line contains the subgenomic
HPV16 expression plasmid pBELsLuc stably integrated into its
genome (Fig. 1A) (Li et al., 2013). It expresses high levels of early
HPV16 mRNAs, in particular E4 mRNAs spliced between SD880
and SA3358 followed by polyadenylation at pAE, but only low
levels of the late mRNAs (Zhao et al., 2004; Orru et al., 2012).
pBELsLuc has the sLuc gene inserted into the L1 coding region of
HPV16 and it serves as a marker for HPV16 late gene expression
(Li et al., 2013). The HPV16 late mRNAs can be induced by
overexpression or knock-down of various proteins and this induc-
tion can be monitored as an increase in secreted luciferase (sLuc)
in the cell culture medium.
To investigate if histone marks on the HPV16 genome, corre-
lated with the high levels of early gene expression or the low
levels of late gene expression in the C33A2 cells, a screening of
various histone marks over the integrated pBELsLuc plasmid in the
C33A2 cells was performed using chromatin immunoprecipitation
(ChIP) assay. First, the MNase digestion of the chromatin was
optimized to produce mononucleosomes and dinucleosomes
(Fig. 1B). that were subjected to ChIP assay with either IgG, or
antibodies to histone H3 or RNA polymerase-II followed by PCR on
the extracted DNA with HPV16 primers (Fig. 1C). These results
revealed that HPV16 DNA could be immunoprecipitated with
antibodies to histone H3 and RNA polymerase-II, but not by IgG
(Fig. 1C). A PCR fragment of the same size was ampliﬁed from
the input chromatin preparation, as expected (Fig. 1C). Having
established appropriate ChIP conditions, the levels of nucleosomes
immunoprecipitated by each antibody were determined by qPCR
as described in section “Materials and methods”. First results
revealed that the levels of total histone H3 and H4 were relatively
similar over the entire HPV16 sequence (Fig. 1D), while levels of
RNA polymerase II on the HPV16 genome decreased somewhat as
the distance from the promoter grew (Fig. 1D). Next we investi-
gated if histone methylation correlated with HPV16 gene expres-
sion levels. We found that the levels of H3K36me3 were lower in
the late region than in the early region (Fig. 1E), which is in line
with previous observations of enrichment of H3K36me3 on exons
and transcribed regions of DNA (Barski et al., 2007; Wagner and
Carpenter, 2012; Spies et al., 2009; Andersson et al., 2009).
Splicing factors of the SR protein family have been shown to bind
H3K36 in a Psip/Ledgf-dependent manner (Pradeepa et al., 2012).
However, the levels of Psip/Ledgf p52 associated with HPV16 DNA
were not higher in the early region than in the early region
(Fig. 1E). Levels of mono-methylated H3K36 (H3K36me1) on the
other hand were similar over HPV16 early and late genes (Fig. 1E).
Presence of H3K9me3 has been shown to correlate with transcrip-
tion repression (Barski et al., 2007; Wang et al., 2008) but is also
enriched over alternatively spliced exons and interact with spli-
cing factors (Saint-Andre et al., 2011). H3K9me3 displayed an
inverse correlation with HPV16 gene expression and was more
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abundant in the HPV16 late region than in the early region
(Fig. 1E), while H3K9me2 was evenly distributed over the HPV16
genome (Fig. 1E). H3K27me3 that has previously been reported to
be enriched over exons and to be associated with splicing factor
HP1alpha (Spies et al., 2009; Andersson et al., 2009) was evenly
distributed over the HPV16 genome (Fig. 1E), whereas H3K4me1
that has not previously been associated with splicing was slightly
less abundant in the HPV16 late region (Fig. 1E). It has been
reported that the histone H2B mark H2BK5me1 is enriched over
exons (Barski et al., 2007; Andersson et al., 2009). However, here it
was more abundant over the HPV16 late genes than the early
genes (Fig. 1F). Analysis of methylation of histone H4 revealed that
H4K20me1 was evenly distributed over HPV16 early and late
genes, while H4K20me3 was more abundant over the late genes
(Fig. 1F) and therefore showed an inverse correlation with HPV16
gene expression levels.
We wished to investigate if altering the levels of histone
methylation affected HPV16 gene expression. Levels of H3K3-
6me3 and H3K4me1 have been shown previously to be low in
poorly expressed cellular genes (Barski et al., 2007; Wagner and
Carpenter 2012; Spies et al., 2009; Andersson et al., 2009), which
correlate well with the lower levels of H3K36me3 and H3K4me1
in the late region of HPV16. These results suggested that
enhanced histone methylation might alleviate inhibition of
HPV16 late gene expression. We therefore investigated if histone
de-methylase inhibitors that would prevent de-methylation of
H3K4me1 (OG-L002 and 2-PCPA), H3K36me3 (NOG, CHQ and
ML234) or H3K27 (GSK J4 HCl) affected HPV16 late gene
expression (Fig. 1G). However, none of the histone demethylase
inhibitors induced HPV16 late gene expression whereas the
positive control substance TPA that has been shown previously
to induce HPV16 (Orru et al., 2012) or HPV31 (Meyers et al., 1992)
late gene expression, induced late gene expression in the
C33A2 cells, which was as measured as an increase in secreted
luciferase activity in the cell culture medium of the C33A2 cells
(Fig. 1G).
High levels of methylated DNA in the late region of HPV16
We also monitored the levels of HPV16 DNA methylation in the
C33A2 cell line using methyl-DNA immunoprecipitation and found
high levels of DNA methylation in the HPV16 late region compared
to the early region (Fig. 1H), suggesting that methylation of HPV16
late DNA suppressed HPV16 late gene expression. However, treat-
ment of the C33A2 cells with either reversible or non-reversible
DNA methyltransferase inhibitors azacytidine and RG108 had no
effect on HPV16 late gene expression (Fig. 1I). In contrast, the
positive control substance TPA did as expected (Fig. 1G).
Low levels of histone H3 acetylation (H3K9Ac) in the HPV16 late
genes but high levels at the early polyA signal
Next we investigated if histone-acetylation on HPV16 nucleo-
somes correlated with HPV16 gene expression levels. As can be
seen from Fig. 2A, the levels of histone 3 acetylation, in particular
H3K9Ac, was signiﬁcantly lower in the HPV16 late region, than in
the early region. In contrast, levels of histone H4 acetylation and
H4K8Ac showed a peak at the promoter, but remained relatively
constant over the HPV16 early and late genes (Fig. 2A). H4K16Ac
was elevated at late 30-splice site SA5639, but otherwise displayed
a similar degree of acetylation in HPV16 early and late genes
(Fig. 2A). We concluded that levels of histone H3 acetylation over
the HPV16 genome, correlated with HPV16 gene expression levels.
Induction of histone H3 and H4 acetylation on the HPV16 genome
correlates with activation of HPV16 gene expression in cervical
cancer cells
To investigate if an increase in histone acetylation would
enhance HPV16 late gene expression we screened a commercially
available library of 21 HDAC inhibitors for induction of HPV16 late
gene expression in the C33A2 reporter cell line. Three HDAC
inhibitors named JNJ-26481585 (also known as quisinostat) (Qui)
(Arts et al., 2009), panobinostat (Pano) (Atadja, 2009) and dual
PI3K/HDAC inhibitor 1 (PI3KI) (Qian et al., 2012) induced HPV16
late gene expression which was monitored as elevated levels of
sLuc activity in the cell culture medium of the C33A2 cells
(Fig. 2B). The induced levels were higher than those induced by
the positive control substance TPA (Fig. 2B) and the effect of the
treatment peaked after 20 h of treatment (Fig. 2C). Combinations
of the drugs revealed an additive effect on HPV16 late gene
expression (Fig. 2D). All three substances caused a signiﬁcant
increase in acetylation of both histones H3 and H4 in the C33A2
cells (Fig. 2E). However, the dual HDAC- and PI3K-inhibitor PI3K/
HDAC inhibitor I was less efﬁcient than the others in inducing
histone acetylation, in particular on histone H3 (Fig. 2E).
To investigate if the HDAC inhibitors affected acetylation of
histones sitting on HPV16 DNA, C33A2 cells treated with either
DMSO alone or DMSO with HDAC inhibitor quisinostat (Qui) were
subjected to ChIP assays. The results revealed that the total levels
of histone H3 and H4 associated with the HPV16 sequences were
unaltered by the HDAC inhibitor as expected (Fig. 3A). The levels
and distribution of the H3K9Ac histone mark were elevated in the
early region of HPV16 as well as in the late region (Fig. 3A), and in
particular over the E4 coding region (amplicon Enh#3) and in the
beginning of L1 (amplicons SA5639 and L1) (Fig. 3A). In contrast,
the levels and distribution of histone 4 acetylation, and the
H4K8Ac and H4K16Ac marks speciﬁcally, were relatively
Fig. 2. (A) ChIP analyses on C33A2 cells using antibodies to proteins indicated in each histogram and qPCR of the indicated amplicons. Primers and antibodies are listed in
Tables S1 and S2 respectively. Mean values with standard deviations of the amount of immunoprecipitated DNA compared to input DNA are displayed. For each antibody, the
values for the CMVtata PCR is set to 1 to correct for differences between different ChIP extracts. White bars represent HPV16 early genes and gray bars represent late genes.
p-Values were calculated for each ChIP result in relation to the CMVtata amplicon. p-Values less than 0.05 (n) or 0.01 (nn) are indicated. All samples were analyzed in two
independent ChIP assays and all qPCR reactions were performed in triplicates. (B) C33A2 cells were seeded in 96-well plates and incubated with the HDAC inhibitor library
(Epigenetic Compound Library, L1900-01) (Selleckchem). Each inhibitor was tested in triplicates at a ﬁnal concentration of 100 nM. Three inhibitors induced signiﬁcant levels
of sLuc from C33A2 cells: Inhibitor 1 (quisinostat/JNJ-26481585), inhibitor 3 (panobinostat) and inhibitor 19 (PI3K/HDAC inhibitor I/CUDC-907). All sLuc measurements were
obtained from at least three independent cell treatments and were analyzed in triplicates. p-Values were calculated with sLuc results from each drug compared to sLuc
results from C33A2 cells incubated with DMSO. p-Values less than 0.05 (n) or 0.01 (nn) are indicated. (C) C33A2 cells were incubated with 100 nM of each HDAC inhibitor
quisinostat (Qui), panobinostat (Pano) or PI3K/HDAC inhibitor I (PI3KI) and the sLuc activity was monitored in the cell culture medium at indicated time points after addition
of drugs. Graph shows mean values and standard deviations of fold induction of sLuc activity of each drug compared to DMSO. All sLuc measurements were obtained from at
least three independent cell treatments and were analyzed in triplicates. (D) C33A2 cells were incubated with 80 nM of each HDAC inhibitor quisinostat (Qui), panobinostat
(Pano) or PI3K/HDAC inhibitor I (PI3KI), or combinations thereof, for 18 h. Graph shows mean values and standard deviations of fold induction of sLuc activity of each drug
compared to DMSO. All sLuc measurements were obtained from at least three independent cell treatments and were analyzed in triplicates. p-Values were calculated with
sLuc results from each drug compared to sLuc results from C33A2 cells incubated with DMSO. All p-values were less than 0.01(nn), as indicated. (E) C33A2 cells were
incubated with 80 nM of each HDAC inhibitor quisinostat (Qui), panobinostat (Pano) or PI3K/HDAC inhibitor I (PI3KI), or combinations thereof, for 18 h. Total protein extracts
were analyzed by Western blotting with antibodies to the indicated proteins. The antibodies used are listed in Table S2.
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unaffected by quisinostat (Qui) (Fig. 3A). We also investigated if
the three HDAC inhibitors identiﬁed in the screen shown in Fig. 2B
differed in their ability to induce acetylation of the HPV16
histones. While none of the inhibitors affected the overall levels
or distribution of histones H3 or H4 over the HPV16 genome
(Fig. 3B), panobinostat enhanced acetylation of H4K8 speciﬁcally
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Fig. 3. (A–C) ChIP analyses on C33A2 cells treated with 80 nM of each HDAC inhibitor quisinostat (Qui), panobinostat (Pano) or PI3K/HDAC inhibitor I (PI3KI) using antibodies
to proteins indicated in each histogram. qPCR of the indicated amplicons are displayed as fold over DMSO treated cells. p-Values were calculated for each ChIP result from
cells treated with HDAC inhibitor in DMSO compared to cells treated with DMSO alone. p-Values less than 0.05 (n) or 0.01 (nn) are indicated. Locations of amplicons in the
HPV16 genome are shown in Fig. 1A and primers and antibodies are listed in Tables S1 and S2 respectively. Mean values with standard deviations are shown. All samples
were analyzed in two independent ChIP assays and all qPCR reactions were performed in triplicates. White bars represent HPV16 early genes and gray bars represent
late genes.
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in the late region of HPV16 (Fig. 3B). Furthermore, abundance of
H3K9Ac on HPV16 early and late genes increased with both Qui
(Fig. 3A) and Pano (Fig. 3C). We concluded that treatment of C33A2
cells with HDAC inhibitors could increase acetylation of H3 and H4
histones in early and late regions of the HPV16 genome. This
increase in histone acetylation on the HPV16 genome was accom-
panied by an increase in HPV16 early and/or late gene expression.
Next we measured the effect of the HDAC inhibitors on the
various alternatively spliced HPV16 mRNAs produced in the C33A2
reporter cell line (Fig. 4A). Since sluc levels were induced by the
HDAC inhibitors, we ﬁrst monitored levels of L1 mRNAs by
standard, end-point RT-PCR (Fig. 4B). While L1 mRNA levels
induced by Pano and PI3KI were readily detected, detection of L1
mRNA levels induced by quisinostat (Qui) required 2–4 more PCR
cycles (Fig. 4B). To assess HPV16 mRNA production more reliably
after incubation with HDAC inhibitors, HPV16 early mRNAs (E1
and E4) and late mRNAs (L2 and L1 or, L2 and L1 combined) were
monitored by RT-qPCR (Fig. 4C). The RT-qPCR assay was performed
on RNA extracted from C33A2 cells incubated in the absence
(DMSO-treated) or presence of either of the three inhibitors
quisinostat (Qui), panobinostat (pano) or PI3K/HDAC inhibitor 1
(PI3KI). The results revealed that the HDAC inhibitors enhanced
expression of HPV16 early and late mRNAs. The increase in the
HPV16 early E1 and E4 mRNAs was roughly four- to eight-fold
(Fig. 4C), while the increase in the late L2 or L1 mRNAs combined
was approximately three- to seven-fold (Fig. 4D). The induction of
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spliced HPV16 L1 mRNAs was slightly lower and was in the range
of two- to four-fold (Fig. 4D), suggesting that the HDAC inhibitors
affected read-through at pAE rather than L1 mRNA splicing. The
HDAC inhibitors induced sLuc production in the same cells, as
expected (Fig. 4E). We concluded that the HDAC inhibitors
increased histone acetylation on both HPV16 early and late genes
and that this induction correlated with activation of both HPV16
early and late gene expression.
E6*I, E7, E1^E4, E5
E6^E7, E7, E1^E4, E5
E6*III, E5
Fo
ld
 m
R
N
A 
le
ve
ls
757s+E4AS
1.0
C3
3A
2
33
10
0.5
p96 p670
SD
22
6
SA
40
9
SA
52
6
SA
74
2 pAE
4215
pAL
7321
SA
56
39
SD
88
0
SD
13
02
SA
25
82
SA
27
09
SA
33
58
SD
36
32
E1
E4 E5
L1
L2
E7
E6
pHPV16ANE2fs
loxPloxP
E2 fs
aa 1
aa 57/58
aa 78
aa 57 aa 78
CAC
H
CAG
Q
GTG
V
CCA
P
GTG
V
CAC
H
CAG
Q
TGG
W
AGG
R
GCC
A
AAC
N
TAA
stop
...
...
E2wt
E2mut
...
...
...
...
...
...
7470
7471
p96 p670
pAE
4215
pAL
7321
E1
E4 E5
L1
L2
E7
E6
pHPV16AN
loxPloxP
7470
7471
E2
aa 1 aa 365
L2
L1
757s
L1ASE4AS
E1F L2F
L1R
RT-PCR 
primers: 
E1R
L1F
L2R
p670E6p97 pALL1SA5639L2pAEEnh#3SA2709E1
amplicons: 
SD
22
6
SA
40
9
SA
52
6
SA
74
2
SA
56
39
SD
88
0
SD
13
02
SA
25
82
SA
27
09
SA
33
58
SD
36
32
072
A
S
91
E hn
E
3#
0.2
1.2
R
el
at
iv
e 
am
ou
nt
 (C
hI
P
/in
pu
t)
E
Ap
2L 365
A
S
9 1L LAp
0.4
0.8
1.0
H3
6
E9p
7
6p
07
0.6
9072
A
S
1
E
E
hn
3#
0.1
0.6
R
el
at
iv
e 
am
ou
nt
 (C
hI
P
/in
pu
t)
E
Ap
2L
A
S
5
936
1L LAp
0.4
H3K9Ac
6
E
79p
076p
0.3
0.5
0.2
S
072
A
91
E #hn
E
3
2.0
R
el
at
iv
e 
am
ou
nt
 (C
hI
P
/in
pu
t)
E
Ap
L2
S
365
A
9 L1 LAp
H4K8Ac
6
E9p
7 76p
0
1.0
1.5
0.5
9072
A
S
1
E
3#hn
E
0.2
0.8
R
el
at
iv
e 
am
ou
nt
 (C
hI
P
/in
pu
t)
E
Ap
2L 9365
A
S
1L LAp
0.6
H3K36me3
6
E
79p
076p
0.4
sonication:
2   10volume (ul):
M - - 5’ 10’ 15’
500 - 
1000 - 
2   10 2   10 2   10
C. Johansson et al. / Virology 482 (2015) 244–259252
Low levels of H3K36me3 and H3K9Ac in the late region of HPV16
in HPV16-immortalized cells
Since the experiments above were all performed in cervical
cancer cells, we wished to study cells representing earlier stages of
the HPV16 infection. We therefore transfected human primary
keratinocytes with a plasmid encoding the full HPV16 genome
(pHPV16AN (Fig. 5A)) to obtain immortalized cell lines. Unfortu-
nately, all cells transfected with HPV16 genomic plasmids encod-
ing the HPV16 wild type E2 gene integrated into the chromosomes
of the keratinocytes, in or near the HPV16 E2 gene. Thus, these
cells could not be used to study the effect of HDAC inhibitors on
HPV16 early and late gene expression. We therefore transfected
the primary keratinocytes with an HPV16 E2-negative mutant of
HPV16 (pHPV16ANE2fs) in which a frame shift mutation was
introduced at amino acid position 58 in E2 (Fig. 5A). This mutation
did not affect any other HPV16 gene. A cell clone named 3310 in
which pHPV16ANE2fs was integrated in the TOPO vector part of
the plasmid and not in E2 was selected (data not shown). The
integrated HPV16 genome in cell clone 3310 could be transcribed
in its entirety and the epigenetic properties of both HPV16 early
and late gene expression could be investigated. However, any role
of HPV16 E2 in then epigenetic regulation of HPV16 gene expres-
sion would be missed. Cell clone 3310 produced similar levels of
HPV16 early mRNAs spliced between SD880 and SA3358 as the
C33A2 reporter cell line (Fig. 5B), whereas late mRNA levels
were low.
We performed a ChIP analysis on chromatin preparations from
the 3310 cells that contained primarily monosomes (Fig. 5C). As
expected, histone H3 showed a relatively even distribution over
HPV16 early and late genes, although a peak of H3 histones was
observed in the E1 region (Fig. 5D). Interestingly, both H3K36me3
and H3K9Ac marks were rare in the late region of the HPV16
genome in the HPV16 immortalized 3310 cells (Fig. 5E), which is in
agreement with the results obtained with cervical cancer derived
C33A2 reporter cell line (Figs. 1E and 2A). These marks were
higher in the early and middle regions of the HPV16 genome, with
the exception of the p97 and p670 promoter regions (Fig. 5E). In
contrast, H4K8Ac was more evenly distributed over the entire
HPV16 genome in the 3310 cells (Fig. 5E), which is also in
agreement with results obtained in the C33A2 cells (Fig. 2A). We
concluded that the pattern of histone marks on HPV16 was similar
in cervical cancer cells and in HPV16 immortalized human
keratinocytes.
Increased acetylation of histones on the HPV16 genome induces
HPV16 early and late gene expression in HPV16 immortalized cells
Since the H3K9Ac was low in the HPV16 late region compared
to the early region, we speculated that addition of HDAC inhibitors
may affect histone acetylation in the HPV16 genome, thereby
inducing HPV16 late gene expression. Addition of the same three
HDAC inhibitors that induced HPV16 late gene expression in the
C33A2 cells: JNJ-26481585/quisinostat (Qui), panobinostat (Pano)
and PI3K/HDAC inhibitor I (PI3KI) caused an increase in global
cellular histone acetylation in the 3310 cells (Fig. 6A). The results
were similar to those obtained with the C33A2 cells, i.e. Qui and
Pano efﬁciently induced histone acetylation whereas PI3KI did so
to a lesser extent (Fig. 6A). Total histone H3, H4 or actin levels
were unaltered by the HDAC inhibitors (Fig. 6A). Furthermore,
none of the methylation inhibitors had any detectable effect on
HPV16 gene expression in the 3310 cells.
Next we investigated if the HDAC inhibitors affected acetylation
of histones on the HPV16 genome. These experiments were
performed with HDAC inhibitor JNJ-26481585/quisinostat (Qui).
As expected, the levels of histone H4 over the HPV16 genome were
relatively unaffected by HDAC inhibitor Qui (Fig. 6B), while the
total levels of acetylated H4 (H4Ac) increased dramatically (up to
45-fold) (Fig. 6C). This increase was particularly apparent in the
HPV16 promoter region and over the HPV16 late genes (Fig. 6C).
Part of the increase in acetylated H4 was attributed to increased
acetylation of H4K8 as H4K8Ac increased around 10-fold over the
entire HPV16 genome (Fig. 6C), while the levels of H4K16Ac were
relatively unaltered (around 1.5-fold increase) (Fig. 6C). Acetyla-
tion of H3K9 over the HPV16 genome also increased dramatically
by HDAC inhibitor treatment and resulted in an up to 17-fold
increase of H3K9Ac in the late region of the HPV16 genome
(Fig. 6C). Similarly to H4Ac, the increase in H3K9Ac was highest
at the HPV16 promoter region and in the late region of the HPV16
genome, while histone acetylation in the E1 region was unaffected
(Fig. 6C). These results suggested that histone acetylation could
potentially affect HPV16 gene expression in the HPV16 immorta-
lized 3310 cells.
To investigate if the HDAC inhibitors also affected HPV16 gene
expression in the HPV16 immortalized 3310 cells, they were
treated with the three HDAC inhibitors JNJ-26481585 Quisino-
stat/Qui, Panobinostat (Pano) and PI3K/HDAC inhibitor 1 (PI3K1).
The results revealed that the HDAC inhibitors Qui and Pano caused
a two-to-three-fold induction of HPV16 early E1 and E4 mRNAs,
whereas HDAC inhibitor PI3KI caused a six-fold induction of both
E1 and E4 mRNAs (Fig. 6D). However, HPV16 late gene expression
was only induced to a minor extent (less than two-fold) (Fig. 6D).
This effect was only seen with primers in the L2 coding region and
not with primers detecting spliced L1 mRNAs (Fig. 6D), suggesting
that the HDAC inhibitors caused a read-through at the HPV16 pAE
rather than an increase in HPV16 late mRNA splicing. We con-
cluded that increased histone acetylation over the HPV16 genome
correlated with an increase in HPV16 early and late gene
expression.
Discussion
A number of histone marks have been shown previously to be
enriched over cellular DNA sequences coding for exons in cellular
genes including H3K36me3, H3K27me1, H3K27me2, H3K27me3,
H3K79me1, H4K20me1 and H2BK5me1 (Barski et al., 2007;
Wagner and Carpenter, 2012; Spies et al., 2009; Andersson et al.,
Fig. 5. (A) Schematic representation of the HPV16 genome in wild type HPV16 plasmid pHPV16AN (Li et al., 2013) and E2-negative mutant pHPV16ANE2fs. The frame-shift
mutation in E2 is indicated. Open reading frames are depicted as rectangles. Early and late promoters p97 and p670, respectively, are indicated as arrows and splice sites as
triangles. The long control region (LCR) and the early and late polyA signals pAE and pAL are indicated. The pHPV16ANE2fs plasmid is integrated in the genome of the HPV16-
immortalized 3310 cells in such a way that the entire HPV16 genome could potentially be transcribed from the HPV16 p97 promoter. The location of each amplicon used for
ChIP analyses is shown. A subset of the HPV16 early mRNAs produced from pHPV16ANE2fs in the 3310 cells is indicated, as well as RT-PCR primers. ChIP primers and RT-PCR
primers are listed in Tables S1 and S3, respectively. (B) The levels of early mRNA spliced from SD880 to SA3358 in the 3310 cells were monitored by RT-qPCR with primers
757s and E4AS and compared to the levels of the same ampliﬁcation production from the C33A2 reporter cell line. Fold difference is shown and (n) indicates a p-value of less
than 0.05. (C) Optimization of sonication conditions to obtain primarily mononucleosomes from the chromatin preparations from 3310 cells. (D, E) ChIP analyses on 3310
cells using antibodies to histone marks indicated in each histogram. Mean values with standard deviations of the amount of immunoprecipitated DNA compared to input
DNA are displayed. qPCR of the indicated amplicons are displayed. Primers and antibodies are listed in Tables S1 and S2 respectively. Mean values with standard deviations
are shown. qPCR of the indicated amplicons are displayed as fold over DMSO treated cells. All samples were analyzed in two independent ChIP assays and all qPCR reactions
were performed in triplicates. p-Values were calculated for each ChIP result in relation to either the p97 amplicon or the pAE amplicon as indicated in the ﬁgure. p-Values
less than 0.05 (n) or 0.01 (nn) are indicated. White bars represent HPV16 early genes and gray bars represent late genes.
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2009). One could therefore speculate that these histone marks
might accumulate in the early region of HPV16, perhaps in
particular downstream of the efﬁciently used HPV16 30-splice site
SA3358. Of these histone marks, we found that H2BK5me1 was
enriched in the late region of HPV16 and as such displayed an
inverse correlation with HPV16 gene expression levels. H3K27me3
and H4K20me1 on the other hand were evenly distributed over
HPV16 early and late genes. We concluded that none of the histone
marks monitored here were enriched over efﬁciently used exons
on HPV16. Other histone marks have been shown to be enriched
over exons and to recruit splicing factors and/or RNA binding
proteins, presumably to enhance chances of splicing silencer or
splicing enhancer recognition by splicing regulatory proteins. For
example, H3K36me3 binds the Psip1/Ledgf p52 protein that
recruits the splicing stimulatory proteins ASF/SF2 (SRSF1) and
SRp20 (SRSF3) (Pradeepa et al., 2012), while under other circum-
stances H3K36me3 interacts with MRG15 that recruits the splicing
inhibitory factor polypyrimidine tract binding protein (PTB) (Luco
et al., 2010). The presence or absence of H3K36me3 may therefore
either promote or inhibit splicing depending on whether SR
proteins or PTB is recruited. In the experiments reported here,
we found that H3K36me3 was rare in the late region compared to
the early region perhaps contributing to inefﬁcient splicing to
SA5639 by lack of recruitment of SR proteins to the HPV16 late
region. However, we were unable to provide support for the idea
that low levels of H3K36me3 in the HPV16 late region prevents
HPV16 late gene expression as all histone de-methylase inhibitors
used here failed to affect HPV16 gene expression. H3K9me3 on the
other hand was more common over the HPV16 late region than
over the HPV16 early genes. This is in contrast to other reports
suggesting that H3K9me3 is enriched on alternatively spliced
exons under conditions that lead to their inclusion in mRNA
(Saint-Andre et al., 2011). Since inhibitory RNA elements in the
HPV16 late region interact with hnRNP proteins hnRNPA1,
hnRNPA2/B1, hnRNPAB, hnRNPD, hnRNPDL, hnRNPE, hnRNPH
and hnRNPK (Zhao et al., 2004; Li et al., 2013; Oberg et al.,
2005; Collier et al., 1998), and it has been shown that H3K9me3
interacts with hnRNPA1, hnRNPA2/B1, hnRNPAB, hnRNPK and
hnRNPL (Vermeulen et al., 2010), one may speculate that
H3K9me3 recruits hnRNPs to the late mRNAs thereby contributing
to suppression of HPV16 late gene expression. This is not without
precedence since both H3K36me3 and H2A.Bbd interact directly or
indirectly with a number of hnRNPs (Pradeepa et al., 2012;
Tolstorukov et al., 2012). Similarly to H3K9me3, both H2BK5me1
and H4K20me3 were enriched over the HPV16 late region de-
monstrating an inverse correlation with HPV16 gene express-
ion. It remains to be determined if the HDAC inhibitors act on
HPV16 transcription or RNA processing or both to induce HPV16
gene expression.
In neuronal cells, hyperacetylation of H3K9 (H3K9Ac) over exon
18 in the neural cell adhesion molecule (NCAM) gene, and histone
H3 and H4 hyperacetylation of exon 23a in the neuroﬁbromatosis-
1 gene and exon 6 of the Fas gene correlates with exon skipping
(Zhou et al., 2011; Schor et al., 2009). Enhanced transcription,
recruitment of splicing inhibitory factors, and lack of recruitment
of splicing stimulatory factors have been suggested to explain the
results. In our experiments, a low concentration of acetylated
H3K9 is observed in the late region of the HPV16 genome and
invariably correlates with low HPV16 gene expression in both
cervical cancer cells and in immortalized human keratinocytes. In
contrast, acetylation of histone H4 is more evenly distributed over
the HPV16 genome, with the exception of H4K16Ac that is more
abundant at HPV16 late L1 splice site SA5639. Treatment of C33A2
cervical cancer cells or HPV16-immortalized 3310 cells with HDAC
inhibitors caused an increase in H4Ac, H4K8Ac, and H3K9Ac over
the entire HPV16 genome in the 3310 cells, or in the late region
speciﬁcally in the C33A2 cells. This increase correlated with an
increase in HPV16 early and late mRNA levels, but did not alter
alternative splicing of HPV16 mRNAs. However, induction of
HPV16 late gene expression was more efﬁcient in the C33A2 cells
than in the 3310 cells, despite a much more pronounced effect on
histone acetylation over the HPV16 genome in 3310 cells than in
C33A2 cells. In contrast, levels of H4K16Ac on the HPV16 genome
were unaffected by the HDAC inhibitors used here, despite a global
increase in H4K16Ac by the HDAC inhibitors. We concluded that an
increase in H3K9Ac and H4K8Ac on the HPV16 genome correlated
with an increase in HPV16 gene expression. Although the increase in
histone acetylation on the HPV16 genome did not speciﬁcally alter
HPV16 mRNA splicing, it did allow increased HPV16 late gene
expression, including production of HPV16 L2 mRNAs and spliced
L1 mRNAs, strongly suggesting that HPV16 splicing and/or polyade-
nylation were affected by epigenetic changes on the HPV16 genome.
A peak in histone H3 acetylation over the HPV16 early polyA
signal pAE was apparent, in particular for H3K9Ac, whereas
acetylation of histone H4 appeared to be indifferent to the
presence of the polyA signal. It has been shown that the HuR
protein can bind HDACs and inhibit their enzymatic activities,
thereby functioning as a local HDAC inhibitor (Zhou et al., 2011).
We have previously shown that overexpression of HuR can induce
HPV16 late gene expression (Johansson et al., 2012). It is not
unreasonable that HuR binds to the U-rich region in the HPV16
early UTR and acts by preventing HDACs from de-acetylating
histone H3 at pAE. Polyadenylation may also be controlled by
histone modiﬁcations (Spies et al., 2009). High levels of HuR would
produce an acetylated zone at pAE, which presumably would have
an impact on the polyadenylation efﬁciency at pAE, and thereby
contributing to the regulation of the switch from HPV16 early to
late gene expression.
HDACs were originally shown to control transcription and high
levels of acetylated histones are common at active promoters as
they open up the chromatin and allow access to transcription
factors that control transcription initiation. It is therefore con-
ceivable that HDAC inhibitors used here affected the promoters of
the reporter construct and/or the HPV16 genomes. However,
induction of HPV16 early and late gene expression in the reporter
cell line C33A2 is not controlled solely at the level of transcription
since replacing the viral late promoter p670 that is silent in mitotic
cells, with the highly active CMV promoter does not cause
induction of HPV16 late gene expression (Zhao et al., 2004).
However, treatment of the C33A2 cells with HDAC inhibi-
Fig. 6. (A) C33A2 and 3310 cells were treated with 80 nM of Quisinostat (Qui), Panobinostat (Pano) and a PI3K inhibitor (PI3K) (alone or in combinations, as indicated) for 18 h. DMSO
was used as control. Total protein extracts were analyzed by Western blotting with antibodies to the indicated proteins. Antibodies are listed in Table S2. (B, C) ChIP analyses on 3310
cells treated with 80 nM of each HDAC inhibitor quisinostat (Qui), panobinostat (Pano) or PI3K/HDAC inhibitor I (PI3KI) using antibodies to proteins indicated in each histogram. qPCR
of the indicated amplicons are displayed as fold over DMSO treated cells. Locations of amplicons in the HPV16 genome are shown in Fig. 5A and primers and antibodies are listed in
Tables S1 and S2 respectively. Mean values with standard deviations are shown. All samples were analyzed in two independent ChIP assays and all qPCR reactions were performed in
triplicates. White bars represent HPV16 early genes and gray bars represent late genes. p-Values were calculated for each ChIP result from cells treated with HDAC inhibitor in DMSO
compared to cells treated with DMSO alone. p-Values less than 0.05 (n) or 0.01 (nn) are indicated. (D) The HPV16 immortalized 3310 cells were treated with 80 nM of quisinostat (Qui),
panobinostat (Pano) or PI3K/HDAC inhibitor I (PI3KI) for 18 h followed by total RNA extraction. DMSO was used as control. RT-qPCR on cDNA of HPV16 early mRNAs (white bars) and
late mRNAs (gray bars) was performed with the indicated primer pairs. Graphs show fold mRNA induction for each inhibitor compared to DMSO from a total of three different
experiments. HPV16 mRNA levels are normalized to GAPDH mRNA levels. RT-qPCR primers are listed in Table S3. Mean values with standard deviations are shown. All RNA analyses
were performed on at least three independent RNA preparations with RT-qPCR performed in triplicate reactions. p-Values were calculated for each RT-qPCR result obtained in the
presence of drug compared to DMSO treatment cells. p-Values less than 0.05 (n) or 0.01 (nn) are indicated.
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tors does. This correlates with an increase in histone acetylation in
both HPV16 early and late genes, suggesting that an overall
increase in histone acetylation is required for induction of HPV16
late gene expression. Our results therefore suggest that acetyl-
ation of intragenic histones contribute to the control of HPV16
gene expression.
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HPV31 E7 has been shown to bind to HDACs and inhibit their
function (Longworth and Laimins, 2004). However, E7 is not
expressed in the C33A2 reporter cell line and is therefore not
interfering with gene expression results or acetylation of internal
histones in the HPV16 genome. However, the 3310 cells were
immortalized by HPV16 and therefore have been selected for
HPV16 E6 and E7 expression. Interestingly, the pattern of histone
acetylation over the HPV16 genome in the cervical cancer cell line
C33A2 and the immortalized keratinocyte cell line 3310, is very
similar, including relatively low histone acetylation in HPV16 early
and late genes and a high peak in histone acetylation at and
around the HPV16 early polyA signal pAE. Therefore, interactions
of E7 with HDACs do not seem to interfere with histone acetyla-
tion of HPV16 induced by the small molecule HDAC inhibitors used
here. However, since HDACs acetylate a variety of cellular proteins,
not just histones (Martinez-Redondo and Vaquero, 2013), we
cannot exclude that the induction of HPV16 gene expression is
the effect of acetylation of cellular protein(s) that are more directly
involved in gene regulation than histones.
Certain histone marks are associated with cancer and loss of
H4K16Ac and H4K20me3 appears to be a hallmark of cancer (Fraga
et al., 2005). H4K16Ac and H4K20me3 were found in normal
keratinocytes, but were lost in benign papillomas, suggesting that
the loss of these two marks may occur early in the carcinogenic
process (Fraga et al., 2005). We did not detect differences in levels
of H4K16Ac between C33A2 cervical cancer cells and the HPV16-
immortalized 3310 cells, neither was H4K16Ac affected by the
HDAC inhibitors used here. However, both H4K16Ac and
H4K20me3 were more prevalent in the HPV16 late region than
in the early region in the cervical cancer cell line C33A2, whereas
H4K16Ac was evenly distributed over the HPV16 genome in the
immortalized 3310 cells. Progression of HPV16 infection to cervical
cancer could potentially be associated with changes of H4K16Ac
and H4K20me3 over the HPV16 genome, in particular in the late
region. It would be of interest to investigate if the histone marks
that correlate with HPV16 gene expression levels such as
H3K9me3, H3K36me3, H2BK5me1 and H3K9Ac show a similar
pattern over HPV16 in HPV16 infected individuals. In particular,
one may investigate if the HPV16 landscape of histone marks
changes in response to disease progression and if it correlates with
severity of the premalignant cervical lesions.
While quisinostat and panobinostat are HDAC-speciﬁc inhibi-
tors (Arts et al., 2009; Atadja, 2009), PI3K/HDAC inhibitor I is a
dual inhibitor that inhibits both HDACs and the PI3K-kinase in the
PI3K/AKT pathway (Qian et al., 2012). Since the dual inhibitor
PI3K/HDAC inhibitor I was less efﬁcient than quisinostat and
panobinostat in inducing histone acetylation in the C33A2 cells
and in the 3310 cells, but induced HPV16 late gene expression to a
similar extent as quisinostat and panobinostat, one may speculate
that other effects on the cells of PI3K/HDAC inhibitor I contributed
to the efﬁcient induction of HPV16 late gene expression. It will
therefore be of interest to investigate if the PI3K/AKT pathway
controls HPV16 gene expression. The apparently lower effect of the
PI3KI inhibitor on histone acetylation observed here may also be
explained by a previously described time-dependent effect of the
PI3KI substance on histone acetylation (Qian et al., 2012). Further-
more, it has been reported that selective induction of apoptosis by
panobinostat in cancer cells, and not in normal cells, correlated
with increased acetylation of histones (Atadja, 2009). However, an
increase in histone acetylation also occurred in the normal cells,
suggesting that panobinostat may act on other cellular proteins as
well (Atadja, 2009). Panobinostat also induces acetylation
of hsp90 and as a consequence, causes a decrease in the levels of
phosphorylated AKT (Atadja, 2009). Taken together, one may
speculate that the PI3K/AKT pathway controls HPV16 gene
expression.
It has been suggested that HDACs promote viral latency, for
example by de-acetylating and silencing the human immunodeﬁ-
ciency virus type 1 (HIV-1) long terminal repeat (LTR) promoter
(Matalon et al., 2011). HDAC inhibitors may therefore be used to
chase latent viruses such as HIV-1 and 2, Epstein Barr virus (EBV)
and herpes simplex types 1 and 2 out of the latency state to
sensitize these infections to antiviral therapy (Ghosh et al., 2012).
It has previously been shown that HDAC inhibitors sodium
butyrate and trichostatin A arrested HeLa cells as well as HPV16
E6/E7 immortalized keratinocytes in G1 to S-transition (Finzer
et al., 2001), and recently HDAC inhibitor vorinostat was reported
to inhibit growth of an HPV11-positive pulmonary tumor in vivo in
one patient (Yuan et al., 2012). One may speculate that HDAC
inhibitors could be used to induce premature late gene expression
in HPV infected cells or in high grade lesions at risk of progressing
to cancer, thereby uncovering the infected cells for the immune
system of the host that could potentially clear the HPV infection.
However, as HDAC inhibitors also induce expression of the early
genes encoding the E6 and E7 oncogenes, treatment of cervical
cancer with or high-grade lesions with HDAC inhibitors could
potentially be contra productive.
Materials and methods
Cell culture
The C33A2 reporter cell line will be described elsewhere.
Brieﬂy, it is derived from the HPV-negative, human cervical
carcinoma cell line C33A, which was stably transfected with the
subgenomic reporter plasmid pBELsluc. C33A2 cells are main-
tained in Dulbecco's modiﬁed Eagle medium containing 10%
bovine calf serum and penicillin-streptomycin.
The 3310 cell line will be described elsewhere. Brieﬂy, it is
derived from neonatal human epidermal keratinocytes (HEKn)
purchased from Gibco Invitrogen Cell Culture stably transfected
with plasmid pHPV16ANE2fs encoding an E2-negative, HPV16 full-
length genome. Brieﬂy, immortalized, G418-resistent colonies
were selected and characterized to obtain a cell clone that contains
the entire HPV16 genome integrated in such a way that the HPV16
genome is uninterrupted. This resulted in the 3310 cell line. The
3310 cell line is propagated in EpiLife Medium supplemented with
Human keratinocyte Growth Supplement (Gibco Invitrogen Cell
Culture) as recommended by the manufacturer. The primary
keratinocytes are grown in monolayer cultures and expanded
under growth conditions that maintain poorly differentiated cells
with properties similar to the cells in the basal layers of the
epithelium.
Inhibitors
The HDAC inhibitor library (Epigenetic Compound Library, L1900-
01) was purchased from Selleckchem. Cell culture medium was
replaced with medium containing indicated concentrations of inhi-
bitor or with 80 nM each of the three different HDAC inhibitors
quisinostat (JNJ-26481585) (Arts et al., 2009), panobinostat (Atadja,
2009) and PI3K/HDAC inhibitor I (CUDC-907) (Qian et al., 2012) for
indicated time periods. DMSO was used as a control. The following
histone de-methylase inhibitors were used at 50 μM as indicated in
each ﬁgure legend: JMJD3 and UTX inhibitor GSKJ4-HCl (S7070
Selleckchem), LSD1 inhibitor OGL-002 (S7237 Selleckchem), tranyl-
cypromine (2-PCPA) (S4246 Selleckchem), JMJD2 inhibitors N-
Oxalylglycine (NOG) (O9390 Sigma), 5-Carboxy-8-hydroxyquinoline
(CHQ) (SML0067 Sigma) and ML324 (Axon 2081 Axon Medchem).
The following DNA methyltransferase inhibitors were used at con-
centrations indicated in each ﬁgure legend: azacytidine (A2385
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Sigma), RG108 (R8279 Sigma). All inhibitors were dissolved in DMSO,
and DMSO in the absence of inhibitor was used as a control in all
experiments.
Secreted Luciferase assay
The secreted Luciferase activity in the medium of the cells was
measured with the Ready To Glow Secreted Luciferase Reporter
assay (Clontech). The collected media was centrifuged at 14,000g
for 5 min, 50 μl of cell culture media was mixed with 50 μl PBS
and 5 μl 0.5 Luciferase substrate in Reaction buffer. The lumi-
nescence was measured in a Tristar Luminometer (Berthold
Technologies).
Western blotting
C33A2 and 3310 cells were lysed using RIPA-buffer (50 mM Tris
pH 7.8, 300 mM NaCl, 1% Na-deoxycholate, 0.1% SDS, 1% Triton X-
100 and protease inhibitors). The 3310 cells were also subjected to
sonication. The protein concentration of each cell extract was
determined and equal amounts of proteins were separated on
SDS-PAGE gels and transferred to nitrocellulose membranes.
Membranes were incubated with primary antibodies to various
histones or actin (Table S2) and Horseradish peroxidase-
conjugated secondary antibody (Sigma). The bands were visua-
lized using The SuperSignal West Pico and Femto Chemilumines-
cent Substrates and images captured with the ChemiDoc MP
System (BioRad).
RNA extraction and reverse transcription
Total RNA was extracted by Tri reagent (Sigma) according to
manufacturers protocol. The RNA was DNase-treated and repreci-
pitated. Two to ﬁve hundred nanograms of total RNA was reverse
transcribed to cDNA in a 25 μl reaction at 42 1C by using ran-
dom hexamers and MLV Reverse Transcriptase (Invitrogen)
according to the manufacturer's instructions. RT-PCR primers are
listed in Table S3.
Quantitative PCR
Quantitative PCR was performed on cDNA or puriﬁed ChIP DNA
using the SsoAdvanced SYBR Green Supermix (BioRad) according
to the manufacturer's instructions. Primer sequences are shown in
Tables S1 and S3. Cycling was performed in the MiniOpticon
System (BioRad). Obtained Ct values were used to calculate the
amount of each immunoprecipitation relative to the input accord-
ing to: Relative amount¼2Ct(IP)/2Ct(input), for each PCR ampli-
con. For drug treatments, the fold change compared to DMSO-
treated samples was calculated according to Fold change¼(2Ct
(IP)/2Ct(input))drug/(2Ct(IP)/2Ct(input))DMSO.
Me-DNA immunoprecipitation
C33A2 cells were lysed in 10 mM Tris pH 8.0, 100 mM NaCl,
25 mM EDTA, 0.5% SDS and 250 μg/ml proteinase K by overnight
incubation at 50 1C. Puriﬁed DNA was RNase-treated, ethanol-
reprecipitated and dissolved in TE buffer. The DNA was sonicated
10–1530 s in a Diagenode Bioruptor with high setting to achieve
DNA shearing to approximately 500–1500 bp fragments. Four
micrograms of sonicated DNA diluted to 450 μl in TE buffer
was used for each immunoprecipitation. The DNA was denatu-
red at 95 1C for 10 min after which 50 μl 10 IP buffer (100 mM
Na-phosphate, pH 7.0, 1.4 M NaCl, 0.5% Triton X-100) was added.
Me-C or control IgG antibodies were added and incubated for 2–4
h at 4 1C. Immune complexes were precipitated by a 2 h end-over-
end incubation at 4 1C with Protein G Magnetic Beads. Beads were
washed three times with 1 IP buffer. Samples were eluted from
the beads with elution buffer (1% SDS, 0.1 M NaHCO3) and
proteinase K treated prior to puriﬁcation of RNA on columns prior
to qPCR. 1% of the extract used for immunoprecipitation was
puriﬁed and used as input control.
Chromatin immunoprecipitation (ChIP) of nucleosomes from
C33A2 cells
Chromatin immunoprecipitations were performed using the
SimpleChIPs Enzymatic Chromatin IP Kit (Cell Signaling) accord-
ing to the manufacturer's instructions but with some adjustments.
In detail, C33A2 cells were cross-linked in 1% formaldehyde for
10 min at room temperature. The cross-linking reaction was
stopped by the addition of glycine to a ﬁnal concentration of
0.125 M. Cells were lysed in Buffer A and the nuclei were
recovered by centrifugation. Nuclei were dissolved in Buffer B
and MNase was added to digest the DNA at a ﬁnal concentration of
0.125 U/μl. Incubation time and amount of enzyme had been
previously titrated to achieve mono- and dinucleosomes. Nuclei
were resuspended in ChIP buffer, incubated on ice for 10 min and
sonicated 10–2015 s using a Diagenode Bioruptor with high
setting. Nuclei were observed in a microscope during sonication to
ensure that sufﬁcient lysis had occurred. Samples were thereafter
subjected to centrifugation and the nuclear extract was recovered.
A small aliquot was RNase and proteinase K treated prior to spin
column puriﬁcation to determine the size and concentration of the
DNA. For immunoprecipitation, nuclear extract corresponding to
10–15 μg of DNA was diluted in ChIP buffer and antibodies
indicated in the ﬁgures were added for an overnight end-over-
end incubation at 4 1C. Antibodies are listed in Table S2. Immune
complexes were precipitated through a two-hour end-over-end
incubation at 4 1C with Protein G Magnetic Beads. Beads were
washed twice with ChIP buffer, twice with ChIP buffer supple-
mented with 500 mM NaCl and ﬁnally twice with ChIP buffer
supplemented with 250 mM LiCl. Each wash was incubated end-
over-end for 5 min at 4 1C. Samples were eluted from the beads
with elution buffer (1% SDS, 0.1 M NaHCO3) and treated with
proteinase K prior to puriﬁcation of the DNA on spin columns
followed by DNA qPCR. 2% of the extract used for immunopreci-
pitation was puriﬁed and used as input control.
Chromatin immunoprecipitation (ChIP) of nucleosomes from HPV16
immortalized 3310 cells
Non-cross linked 3310 cells were lysed in 50 mM Hepes, pH 7.9,
140 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.25% Triton X-100, 2.5%
glycerol and protease inhibitors for 1 h on ice. The intact nuclei were
recovered by centrifugation at 14,000 rpm for 1 min. The nuclei were
dissolved in 20 mM Tris pH 8.2, 150 mM NaCl, 2 mM EDTA, 0.1% SDS,
1% Triton X-100, protease inhibitors, incubated for 15 min on ice
followed by sonication for 10 min (2030 s) using a Diagenode
Bioruptor with high setting to disrupt the nuclei and shear the DNA.
The DNA fragments were between 200 and 1000 bp. The nuclear
extracts were recovered by centrifugation at 14,000 rpm for 10 min.
A small aliquot was RNase and proteinase K treated prior to
puriﬁcation of DNA on spin columns to determine the size and
concentration of the DNA. For immunoprecipitation, nuclear extracts
corresponding to 5 μg of DNA were diluted in ChIP buffer and
antibodies were added for overnight end-over-end incubations at
4 1C. Antibodies are listed in Table S2. Immune complexes were
precipitated by a 2 h end-over-end incubation at 4 1C with Protein G
Magnetic Beads. Beads were washed twice with ChIP buffer, twice
with ChIP buffer supplemented with 500 mM NaCl and ﬁnally twice
with ChIP buffer supplemented with 250 mM LiCl. Each wash was
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incubated end-over-end for 5 min at 4 1C. Samples were eluted from
the beads with elution buffer (1% SDS, 0.1 M NaHCO3), proteinase K
treated and subjected to DNA puriﬁcation on spin columns prior to
qPCR. 2% of the extract used for immunoprecipitation was puriﬁed
and used as input control.
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